# Cannabidiol - an in Vivo Innovative Drug Delivery Study

> **NCT03471559** · PHASE1 · TERMINATED · sponsor: **Central Institute of Mental Health, Mannheim** · enrollment: 8 (actual)

## Conditions studied

- Pharmacokinetics, Bioavailability

## Interventions

- **DRUG:** Cannabidiol

## Key facts

- **NCT ID:** NCT03471559
- **Lead sponsor:** Central Institute of Mental Health, Mannheim
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-10
- **Primary completion:** 2019-06-30
- **Final completion:** 2019-08-29
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Two step study, step two was not feasible based on results from phase one.
- **Last updated:** 2020-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03471559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03471559, "Cannabidiol - an in Vivo Innovative Drug Delivery Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03471559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*